Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
Search
Clinical Studies
Clinical Studies
Patient documentary - From diagnosis to everyday living
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Fostering Science
Fostering Science
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Julia Sonnermann
Julia Sonnermann on transforming lives for generations
Aiko Watabe
Prioritizing development with Aiko Watabe
Where to meet us
Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.
Boehringer Ingelheim Office Hours Video 2023
Boehringer Ingelheim’s Office Hours program provides mentoring and access to expertise to help early-stage companies advance their science.
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Vaccines
Vaccines
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Transforming Science Day
How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Covid19 relief program Ghana Cowtribe parasiticides
Boehringer Ingelheim and Cowtribe are kicking off a vital relief initiative in Ghana.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler